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Abstract
Background: DNA methyltransferase (DNMT) is one of the major factors mediating the methylation of cancer related genes
such as TGF-b receptors (TbRs). This in turn may result in a loss of sensitivity to physiologic levels of TGF-b in aggressive
prostate cancer (CaP). The specific mechanisms of DNMT’s role in CaP remain undetermined. In this study, we describe the
mechanism of TGF-b-mediated DNMT in CaP and its association with clinical outcomes following radical prostatectomy.
Methodology/Principal Findings: We used human CaP cell lines with varying degrees of invasive capability to describe how
TGF-b mediates the expression of DNMT in CaP, and its effects on methylation status of TGF-b receptors and the invasive
capability of CaP in vitro and in vivo. Furthermore, we determined the association between DNMT expression and clinical
outcome after radical prostatectomy. We found that more aggressive CaP cells had significantly higher TGF-b levels,
increased expression of DNMT, but reduced TbRs when compared to benign prostate cells and less aggressive prostate
cancer cells. Blockade of TGF-b signaling or ERK activation (p-ERK) was associated with a dramatic decrease in the expression
of DNMT, which results in a coincident increase in the expression of TbRs. Blockade of either TGF-b signaling or DNMT
dramatically decreased the invasive capabilities of CaP. Inhibition of TGF-b in an TRAMP-C2 CaP model in C57BL/6 mice
using 1D11 was associated with downregulation of DNMTs and p-ERK and impairment in tumor growth. Finally,
independent of Gleason grade, increased DNMT1 expression was associated with biochemical recurrence following surgical
treatment for prostate cancer.
Conclusions and Significance: Our findings demonstrate that CaP derived TGF-b may induce the expression of DNMTs in
CaP which is associated with methylation of its receptors and the aggressive potential of CaP. In addition, DNMTs is an
independent predictor for disease recurrence after prostatectomy, and may have clinical implications for CaP
prognostication and therapy.
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TGF-b is a pleiotropic growth factor that has been implicated in
multiple, and often diametrically opposed functions, including cell
proliferation, cell growth arrest, differentiation, and apoptosis [1],
[2]. An obvious question raised by these diverse functions is how
TGF-b mediates these seemingly contradictory roles in both
cancer and benign cells. In cancer cells, TGF-b acts as a growth
promoter and aids in metastasis, whereas in normal cells it appears
to inhibit cell growth and induce apoptosis [3]. Characteristics of
aggressive prostate cancer (CaP) include a gradual loss of
sensitivity to TGF-b and over-expression of TGF-b, which appears
to initiate a vicious cycle for tumor progression. Although it is well
known that a reduction or loss of expression of TGF-b receptors
(TbRs) enables cancer cells to escape the growth inhibitory effect
of TGF-b and to gain a growth advantage, the cellular
mechanism(s) underlying these events in human CaP cells remains
undefined. Previously, we have demonstrated that the loss of TbRs
expression by promoter methylation is associated with insensitivity
to TGF-b-mediated growth inhibition [4].
DNA methylation is carried out by DNA methyltransferases
(DNMTs). There are at least three functional DNMTs that have
been identified in eukaryotic systems. DNMT1 has been implicated
primarily in the maintenance of methylation patterns that occurs
during cellular replication, and it preferentially methylates hemi-
methylated DNA [5]. It has been the most extensively studied
maintenance methyltransferase and is abundant in tumor cells and
tissues. In comparison, DNMT2 does not appear to have significant
methylation activity and DNMT3L is likely to be limited to DNA
methylation during germline development [5]. Finally, DNMT3A
and DNMT3B are known to be de novo methylators of CpG sites
[6], which have higher methyltransferase activity for unmethylated
DNA than DNMT1 and can contribute to de novo methylation
during embryogenesis [7], [8]. Although DNMT is reported to be
associated with some aggressive cancers like hepatocellular
carcinomas, stomach cancers, non-small cell lung cancers, lympho-
ma and prostate cancers [9], [10], [11], [12], [13], its role remains
controversialandtheoverall regulation, coordination and activity of
DNMTs is unclear with different cancers. Furthermore, the
mechanism of DNMTs in cancer cells and its association with
invasive malignant capabilities and clinical outcomes after treat-
ment have not been described.
We recently reported that the epigenetic regulation of TGF-b-
induced expression of Foxp3 may be mediated through the
inactivation of extracellular signal-regulated kinases (ERK), which
may down-regulate DNMTs in benign cells [14]. As stated above,
CaP cells and tissue are insensitive to TGF-b-mediated growth
inhibition and have promoter methylation patterns which decrease
the expression of TbRs (TbRI and TbRII) [4], [15], [16]. Taken
together, these results indicate that the insensitivity to TGF-b in
some CaP cells is at least partly due to the promoter methylation of
TbRs. These findings have led us to explore the following two
hypotheses in the present study: 1) There may be crosstalk
between tumor derived TGF-b and DNMTs which is related to
methylation in cancer; 2) DNMTs may be closely associated with
the prostate cancer progression and outcomes following radical
prostatectomy. To our knowledge, this subject matter has yet to be
reported.
The purpose of our study was several-fold. First, we sought to
investigate the corresponding changes in DNMT and TbRs
expression and ERK activation after treating CaP cells with
varying degrees of invasive capability and benign prostate
epithelial cells with TGF-b. Next, we examined the effect of a
neutralizing TGF-b antibody on the expression of DNMTs and
tumor growth in vivo using a xenograft model. Finally, we
determined whether activation of DNMTs was associated with
biochemical recurrence following radical prostatectomy.
Materials and Methods
(A detailed explanation is presented in Method S1)
Cell Lines
The mouse CaP cell line TRAMP-C2 cells was obtained from
Dr. N. Greenberg [12]. The benign human prostate epithelial cell
line, RWPE-1, was purchased from American type culture
collection (ATCC). BPH-1 cells were kindly provided by Dr.
Simon Hayward. Four variants of the human CaP PC-3 cell lines
(PC-3, PC-3M-Pro4, PC-3M and PC-3M-LN4) with varying
degrees of invasive capabilities were kindly provided by Dr. Fidler
and Dr. Pettaway [17], [18], [19], [20]. The reason we chose PC-3
variants was because these variants originate from the same cell
line, but vary in their aggressive capabilities. The results of
signaling regulation were more comparable in contrast to using the
different kinds of CaP cell lines. For some experiments, cells were
rendered insensitive to TGF-b (as a negative control) by
introducing a TbRIIDN as previously described [21], [22]. In
some experiments, cells were treated with or without TGF-b1o r
MEK inhibitor U0126 (Promega). Finally, some experiments
involved the use of Anti-TGF-b (1, -2, -3) neutralizing mAb (clone
1D11; a gift from Genzyme Corporation) as previously described
[23], [24]. (Method S1).
TGF-b1 ELISA
RWPE-1, BPH-1 and all PC3 variants and the corresponding
TbRIIDN infected cell lines were cultured in fresh serum-free
media for 24 hours. TGF-b1 ELISA was carried out using the
Human TGF-b1 Immunoassay Kit (R&D Systems) (Method S1).
[
3H]-Thymidine Incorporation Assay
All cells were grown in culture for 48 hours. Cells were then
exposed to a medium containing [
3H]-thymidine (0.5 mCi/mL;
Amersham Biosciences) for an additional 5 hours. Thymidine
incorporation was expressed as the fraction of counts found in cells
of untreated controls (Method S1).
Western blot analysis
Western blot analyses were performed to compare TbRs,
DNMTs and ERK expression after different treatments over time
(Method S1).
Methylation-Specific PCR (MSP) and Sequencing
MSP for the methylation status of TbRs was performed
according to our previous report [4]. The methylated sites in
cytosine positions with/without treatment of 5-Aza or TGF-b
were identified.
Immunofluorescence and Co-staining
Immunofluorescence studies were performed on all PC-3 cell
line derivatives as previously described [22], [25]. For co-
localization of DNMTs and phosphorylated ERK (p-ERK), cells
were analyzed by using nucleus (DAPI)-DNMTs(TR)-p-ERK
(FITC) triple staining (Method S1).
Quantitative RT-PCR
Human benign prostate epithelial cells RWPE-1 and BPH-1,
and CaP PC-3 serials) were cultured in fresh media for 24 hours,
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b1 (10 ng/ml), 2) anti-TGF-b neutralizing monoclonal Ab (1D11;
5 mg/ml), or 3) MEK inhibitor U0126 (5 mM). Total RNA was
extracted using an RNeasy kit (Qiagen). Primers for human for
DNMTs [26] and TbRs [4] were listed in Method S1.
Cell invasion assay
Cell invasion assay (Matrigel invasion assay) was done in a 24-
well Transwell chamber (8 mm pore size; CytoSelect; Cell Biolabs).
Cells were plated at a density of 0.5610
6 to 1.0610
6/mL in
serum-free medium. TGF-b1 and/or Erk inhibitor UO126, 5-Aza
were added directly to the cell suspension, and 24 h later, the
suspension was aspirated and the invaded cells were counted with
a light microscope under high magnification objective (6100;
Olympus) and measured at A560 nm in a plate reader after
treatment with the extraction solution.
Animal Studies
The study was initiated using the subcutaneous (sc) injection of
mouse prostate cancer TRAMP-C2 cells transfected with HSV1-
tk-GFP-luciferase (SFG-nTGL) reporter gene expression vector
[27], [28] into the right flank region of 30 C57BL/6 mice as
described earlier [25]. Animals were randomly assigned to one of
three groups following intraperitoneal injections with the specific
anti-TGF-b neutralizing antibody 1D11 or control antibody 13C4
as described before [23,24]. All the mice were sacrificed after 15
injections of antibodies and group 3 were sacrificed on the same
time interval. (Method S1). This study received approval from the
institutional review board of Northwestern University (Evanston,
IL). Northwestern University ACUC Approval protocol number
2007-0565.’’ (Letter S1).
Construction of Tissue Microarrays (TMAs) and Clinical
Outcome Assement
The existing clinical case information and banked tissue
established within our prostate SPORE program database at
Northwestern University was used. All enrolled subjects provided
written informed consent by Northwestern Memorial Hospital and
the study was approved by the Northwestern University
Institutional Review Board (The IRB number is 1480-002, Letter
S2). A total of 243 radical prostatectomy specimens were available
with associated clinical information. A series of prostate TMAs
were constructed with formalin-fixed, paraffin-embedded radical
prostatectomy specimens as described previously [4], (Method S1
and Method S2).
Immunohistochemistry
All antibodies raised against DNMTs, phosphorylated ERK (p-
ERK), total ERK (t-ERK), phosphorylated Smad2, TbRI and
TbRII were first tested and optimized on whole-tissue sections and
test arrays as previously described [4], [17], [29], [30], (Method S1
and Method S2).
Statistical Analysis. The SPSS 10.0.7 software package
(SPSS, Inc.) was used for all analyses. Kaplan-Meier survival curve
was analyzed by the log-rank test using the Graphpad Prism 4.02
software (Graphpad Software) (Method S1).
Results
1. DNMTs expression is associated with down regulation
of TbRs and more invasive prostate cancer phenotypes
An ELISA assay was initially performed to determine whether
there were differences in the endogenous expression levels of TGF-
b in different CaP cell lines when compared to benign prostate cell
lines. We found that all PC-3 cell lines expressed significantly
higher levels of TGF-b (62 to 6 times) compared to the BPH-1
and RWPE-1 (p,0.05). Furthermore, we found that more invasive
cells (PC-3M and PC-3M-LN4) secreted almost 2 times higher
baseline levels of TGF-b1 when compared with the less invasive
cell lines (PC-3 and PC-3M-Pro4) (Fig. 1A).
We confirmed that different prostate cell lines behave differently
in response to exogenous TGF-b1 exposure. For example, we
found that RWPE-1 and BPH-1 cells were most sensitive to
exogenous TGF-b1 as their growth was inhibited by 64.1% and
61.9%, respectively, after 24 hours of treatment with TGF-b1. In
comparison, PC-3 and PC-3M-Pro4 cells were only inhibited by
13.7% and 12.3%, respectively. Finally, the growth rate of PC-
3M-LN4 and PC-3M was unaffected by TGF-b1 exposure
(Fig. 1B). Interestingly, in CaP cell lines, inhibition of TGF-b
signaling, using the dominant negative type II TGF-b receptor
(TßRIIDN) construct, was associated with significantly higher
endogenous TbRII expression (using antibodies directed against
the intracellular domain, because TbRIIDN includes only
extracellular and transmembrane domains, but not intracellular
domain) (Fig. 1C) and higher TGF-b secretion (Fig. 1D). In
comparison, there was no difference in the expression of TGF-b in
BPH-1 or RWPE-1 when they were infected with the retroviral
TbRIIDN construct (Table S1).
In contrast to the expression of TGF-b, both TbRI and TbRII
expression was significantly reduced in the more invasive cell lines,
PC-3M-LN04 and PC-3M, compared with PC-3 and PC-3M-
Pro4 cells (Fig. 2A). Blockade of TGF-b signaling with the
TbRIIDN vector caused an approximately two to ten-fold increase
in the expression of both TbRI and TbRII in all CaP cell lines
(Fig. 2B). Taken together this suggests that increased baseline
levels of TGF-b are associated with the inhibition of TbRs
expression. Blockade of intracellular TGF-b signaling resulted in
up-regulation of secretion of TGF-b in cancer cells.
Since promoter methylation of TbRs is associated with
decreased expression [4], we compared the expression levels of
DNMTs in the different CaP cell lines. In general, the more
invasive PC-3M-LN4 and PC-3M cells showed an increased
expression of DNMTs, when compared to the less invasive PC-3
and PC-3M-Pro4 (Fig. 2C). Blockade of TGF-b signaling with the
TbRIIDN vector caused a $3-fold decrease in the expression of
DNMTs in all CaP cell lines (Fig. 2D), and there was a
corresponding increase in the expression of both TbRI and
TbRII (Fig. 2B). The corresponding value (relative ratio of TbRs/
GAPDH, or DNMTs/GAPDH) is shown in right panels. This
finding was also supported by additional confirmatory studies.
Immunoblot analyses demonstrated that after treatment with 5-
Aza-29-deoxycytidine (5-Aza), the expression of TbRI and TbRII
in PC-3 increased dramatically. In contrast, the expression of both
TbRI and TbRII decreased significantly with the treatment of
TGF-b and this change could be recovered when 5-Aza is added
(Figure S1A). Similarly, real-time PCR confirmed that the
expression of both TbRI and TbRII was increased 2 to 2.5 folds
after treatment of 5-Aza in PC-3 cells. Treatment with TGF-b
suppressed the expressions of TbRI and TbRII 46% and 29%
respectively (Figure S1B). We also identified the methylation status
of TbRI and TbRII promoters, by using the same MSP approach
and sequencing methodologies [4]. Using this technique, we found
the same methylated sites as our previous study [4] in that cytosine
positions 2251, 2231, 2244, 2348, 2356 and 2365 in the
promoter of TbRI, and +27, +32 and 2140 for the promoter of
TbRII were methylated (Figure S1C). PC-3 cells also have a
portion of TbRI and TbRII promoters that are unmethylated.
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25168Figure 1. Tumor derived TGF-b regulates the expression of TbRs and secretion of TGF-b.A .ELISA assay demonstrating that PC-3 cell lines
express significantly (p,0.05) higher (62–6 times) levels of TGF-b compared to benign prostate cell lines, BPH-1 and RWPE-1. Furthermore, PC-3M
and PC-3M-LN4, secreted almost 2 times higher baseline levels of TGF-b1 compared to PC-3 and PC-3M-Pro4 cells, respectively, which are less
invasive. B. A thymidine incorporation assay indicates that the growth of RWPE-1 and BPH-1 cells is inhibited significantly by exposure to TGF-b1. In
comparison, the growth of PC-3 and PC-3M-Pro4 cells is only slightly inhibited, and PC-3M-LN4 and PC-3M cells show no significant response to TGF-
b1 exposure. C. In all cancer cell lines (here we show PC-3 as an example), inhibition of TGF-b using the TbRIIDN construct results in significantly
higher naı ¨ve TbRII expression, and D. higher TGF-b secretion. Similar findings are found in the findings in the more invasive cell lines. In comparison,
there was no difference in the expression of TbRII in BPH-1 or RWPE-1 when they were infected with TßRIIDN (Table S1).
doi:10.1371/journal.pone.0025168.g001
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25168Interestingly, treatment with TGF-b increased the methylation
status, but treatment with 5-Aza converted all methylated sites to
unmethylated. The thymidine incorporation assay indicated that
the proliferation of PC-3 cells were only modestly inhibited
modestly by exogenous TGF-b. In comparison, 5-Aza treatment
resulted in significant inhibition of cell proliferation, regardless of
whether exogenous TGF-b was added into the culture or not.
There was no significant difference observed between treatment
with both 5-Aza and TGF-b or with 5-Aza alone (P.0.05) (Figure
S1D).
2. DNMTs expression is mediated through a
phosphorylated-ERK dependent pathway
Our previous studies demonstrate that ERK may influence
DNMT expression in benign cells [14]. We therefore sought to
determine whether the level of activated ERK (phosphorylated
ERK; p-ERK) is related to TGF-b-induced expression of
DNMTs. To test this hypothesis, we first determined the level of
p-ERK in benign prostate cells and compared it to the levels in
different CaP cell lines. BPH-1 and RPWE-1 cells expressed
significantly higher baseline levels of p-ERK than PC-3 cells
(Fig. 3A). Interestingly, the time course of p-ERK expression after
exposure to TGF-b was different between the benign and
malignant cell lines. Specifically, there was a time dependent
positive correlation between treatment with TGF-b1 and the
expression of p-ERK in all PC-3 cell lines. In fact, this rapid
increase in p-ERK expression (4-fold) began within 5 minutes
following TGF-b1 treatment. The levels of p-ERK continued to
increase during all subsequent time points up to 30 minutes after
TGF-b1 addition. In contrast, the expression of p-ERK was
rapidly inhibited (,5 minutes) after TGF-b1 addition to the media
of benign cells, in a fashion that was independent of the total ERK
protein expression (Fig. 3A). Immunofluorescence studies were
subsequently used to help determine whether p-ERK and DNMTs
were co-localized to the same cellular regions. To this end,
confocal microscopic analyses of formaldehyde fixed immuno-
stained PC-3 cells, in the absence or presence of TGF-b1,
demonstrated co-loczalization between p-ERK and DNMTs
signals. Only the cells with p-ERK immunofluorescence exhibited
DNMT expression. In contrast, when PC-3 cells were rendered
insensitive to TGF-b1 by transfection with the TbRIIDN, levels of
both p-ERK and DNMTs were reduced dramatically as
determined by immunofluorsence staining (Fig. 3B). To better
quantify this relationship between TGF-b1, p-ERK and DNMTs,
we next used real time PCR. These results demonstrated that
exposure to TGF-b1 for 24 hours significantly increased the
expression of all three DNMTs (,16.7%–14%) in all PC-3 cell
lines studied. Treatment with an antibody specific for TGF-b1
(1D11; 5 mg/ml) or the specific ERK inhibitor, UO126, led to
significant down-regulation of DNMTs mRNA expression
(,33.9%–52.3%, and ,41.5%–57.6% respectively, Fig. 3C).
These results suggest that TGF-b mediated expression of DNMTs
is associated with an increase in p-ERK in cancer cells.
Specifically, tumor derived TGF-b appears to be responsible for
this ERK activation, as blockade of the original secreted TGF-b
resulted in a great change in the expression of DNMTs (Fig. 3C).
These results also suggest that tumor derived TGF-b mediated
ERK activation is at least one of the major mediators for TGF-b
induced expression of DNMTs which lead to TbRs down-
regulation by promoter methylation in CaP [4], [14]. After
treatment with TGF-b, there was a significant increase in the
invasive capabilities of CaP cells. Invasion of CaP cells was
inhibited by either TGF-b inhibitor 1D11, or p-Erk inhibitor
U0126 or DNMT inhibor 5-Aza. The inhibition of invasion by the
U0126 could not be reversed by TGF-b1 treatment. Importantly,
DNMTs inhibitor 5-Aza can dramatically inhibited the CaP cells
invasion, even more than blockade of TGF-b or p-ERK (Fig. 3D).
This observation suggested that p-ERK was downstream factor of
TGF-b, and synergistically mediates TGF-b regulated DNMTs
which was closely associated with the invasive capability of CaP
cells.
3. In vivo validation of the effects of TGF-b on ERK
activation, DNMT expression, and prostate cancer growth
To validate whether TGF-b is responsible for the activation of
ERK and up-regulation of DNMTs which may be involved in
tumor progression in vivo, we conducted experiments using a
mouse xenograft CaP model which involved the injection of CaP
tumor cells (TRAMP-C2 cells stably transfected with a HSV1-tk-
GFP-luciferase reporter, 5610
6/each mouse). Tumor growth was
followed using luciferase imaging. We used three groups of mice to
better understand the effects of TGF-b on ERK activation and
DNMT expression: Group 1: mice (n=10) received regular
injections of the TGF-b neutralizing antibody, 1D11. Group 2:
mice (n=10) received the isotype control antibody, 13C4, at the
same regular intervals as Group 1. Group 3: received no treatment
after xenograft injection as a control. We found that tumor growth
was significantly inhibited with anti-TGF-b 1D11 antibody,
treatment (Group 1) compared with the other two groups
(Fig. 4A, 4B). In fact, at the end of the 45-day treatment period,
one of the ten mice (10%) in this group was free of tumor. In the
remaining 9 mice, the average tumor weight and volume was 5.3 g
and 6.85 cm
3, respectively. In comparison, tumors were found in
all mice in Groups 2 and 3. The average weight and volume of
tumors in the 10 animals treated with the control antibody (Group
2) or no treatment (Group 3) was significantly greater (Fig. 4C).
There were no metastases in all the groups as assessed by
bioluminescence imaging. Immunohistochemical analyses of the
primary tumors revealed that the expression of p-ERK and
DNMTs in animals in Group 1 were significantly lower than those
of the other two groups (Fig. 4D).
4. DNMTs correlates with clinical characteristics
To evaluate the association between TGF-b and the induction
of DNMTs in CaP specimens, we compared the expression levels
of TGF-b1, ERK, p-ERK, TbRI, TbRII, p-Smad2, and DNMTs
in archived tissue microarray specimens obtained at the time of
radical prostatectomy and correlated them with corresponding
patients’ clinical and pathologic characteristics (Table S2. Each
marker was assigned a value of 0 (,20% cell immunostaining), 1
Figure 2. TGF-b induced expression of DNMTs is inversely associated with the expression of TbRs. A. Western blot analyses demonstrate
that in contrast to the expression of TGF-b, both TbRI and TbRII expression (as described in Figure 1B) is significantly reduced in the more invasive cell
lines compared with less invasive cell lines. B. Blockade of TGF-b signaling with the TbRIIDN causes significant increase in the expression TbRIs in all
cell lines. C. In contrast to the expression of TbRs, the over expression of DNMTs is associated with more invasive cell lines compared with the less
invasive cell lines. D. Blockade of TGF-b signaling with TbRIIDN caused a $3-fold decrease in the expression of DNMTs. The corresponding value
(relative ratio of TbRs/GAPDH, or DNMTs/GAPDH) is shown in right charts. (Fig. 2A and 2B were from the same Western Blot image, and Fig. 2C and
2D were from the other single Western blot image).
doi:10.1371/journal.pone.0025168.g002
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25168Figure 3. TGF-b induced DNMTs is mediated by ERK activation. A. The benign BPH-1 and RPWE-1 cells express significantly higher baseline
levels of p-ERK than the PC-3 cells. There is a time dependent positive correlation between treatment with TGF-b1 and the expression of p-ERK in PC-
3 cells. The levels of p-ERK continue to increase during all subsequent time points up to 30 minutes after TGF-b1 addition. In contrast, the expression
of p-ERK is rapidly (,5 minutes) inhibited after TGF-b1 exposure in benign cells in a fashion that is independent of the total ERK protein expression.
B. Immunofluorescence reveals that only cells (this is PC3 for example) expressing p-ERK exhibit DNMT expression. In contrast, when PC-3 cells are
rendered insensitive to TGF-ß1 by TbRIIDN, levels of both p-ERK and DNMT are significantly reduced (magnification: 10620). C. We performed real
time PCR to better quantify the relationship between TGF-b1, p-ERK and DNMTs. Exposure to TGF-b1 significantly increased the expression of all
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and 3 (75–100% cell immunostaining) depending on the
percentage of cancer cells showing positive immunostaining. The
positive and negative control staining was showed in the ‘‘Figure
S2’’. We found that a high level of expression of TGF-b1, p-ERK
and DNMTs coupled with a low level of expression of TbRI,
TbRII, and p-Smad2 was associated with adverse pathologic
features, such as higher Gleason’s grade (Fig. 5A, Fig. 5B, Table
S3). These results correspond to our finding in PC-3M-LN4 and
PC-3M cells that TGF-b induced DNMTs are associated with
clinically more aggressive phenotypes.
We found a significant correlation between the expression of
TGF-b1 and DNMTs in these tissue microarray specimens. There
was also a significant correlation between TGF-b and p-ERK,
TGF-b and TbRI, p-ERK and DNMT1, p-ERK and DNMT3A,
p-ERK and DNMT3B respectively. In addition, we found a
significant correlation between the expression levels of all three of
the DNMTs. There were inverse relationships between DNMTs
and TbRs, DNMT1.vs. TbRI, DNMT1.vs. TbRII, DNMT3A vs.
TbRII (Table S3).
5. DNMTs is associated with biochemical recurrence in
prostate cancer patients after radical prostatectomy
To examine the utility of these markers as possible prognostic
tools, we correlated the expression levels of the above TGF-b
related biomarkers of each tumor with the clinical outcome of the
corresponding patient using the database of Northwestern
University’s Prostate SPORE. The log rank test was used
determine whether or not these various markers correlated with
biochemical recurrence (PSA.0.2 ng/ml after radical prostatec-
tomy). Variables of interest included all TMA markers, clinical
stage, clinical Gleason’s score, which was grouped as 4–6, 7, 8–10,
surgical margin status, PSA doubling time, and patient age. As
mentioned above, all specimens were assigned a value between 0–
3 based upon the percentage of cancer cells showing a positive
staining. A Kaplan Meier curve was generated for each of the
above significant variables.
Expression levels of TGF-b1, p-Smad2, p-ERK, pathologic
Gleason Score and DNMT1, TbRI were associated with
biochemical recurrence after radical prostatectomy (Fig. 6A. B,
Table S4). The degree of DNMT1 expression correlated
significantly with biochemical recurrence [P=0.0043 using 4
expression groups; (0, 1, 2, 3; P=4610
204 using 2 groups; low
expression (0, 1, 2) vs high expression(3)]. DNMT3A and
DNMT3B, surgical margin status, TGF-b type II receptor
expression level and PSA doubling time were not associated with
biochemical recurrence (p.0.05). To determine the best model for
predicting PSA recurrence, a Cox Proportional Hazards Model
was fit to include all the significant variables and backward
selection method was used to eliminate non-significant variables.
The final selected model includes DNMT1, grouped as below 3
(low expression) or above 3 (high expression; log Rank P=0.002;
hazard ratio=3. 53; 95% CI 1.6–7.78), and pathologic Gleason
score sum of patients, grouped as below 8, or above (log Rank
P=0.034; hazard ratio=2.27; 95% CI 1. 06–4.83) (Fig. 6C, Table
S5). Patients whose tumors had a DNMT1 expression level of 3
(high expression) had a 3.53 higher risk of recurrence than patients
with lower scores of DNMT1 in the tumor. Even in patients with
low Gleason grade (#6), there was a high risk of recurrence if high
levels of DNMT1 expression were present. A high DNMT1
expression was independently associated with biochemical recur-
rence, irrespective of Gleason score. There was no correlation
between PSA doubling time and the expression levels of DNMT1.
Discussion
Many malignancies, including CaP, exhibit aberrant methyla-
tion within the promoter regions of genes associated with a loss of
function [31], [32], [33]. Presumably, this loss of function
contributes to the development and progression of the disease.
DNMTs are the major mediators responsible for the hypermethy-
lation of the promoter regions of many genes encoding for
signaling factors including the TbRs promoter [4], which may
subsequently inhibits TbRs translation which ultimately results in
the insensitivity to the normal inhibitory effects of TGF-b,
uninhibited growth and progression of cancer [4], [34], [35],
[36]. Although DNMTs are recognized as important regulators of
transcription of carcinogenesis [37], [38], [39], [40], [41], [42],
and have been a topic of considerable interest in the last few years,
their assessment in vivo and within human specimens remains
uncertain. Our study findings demonstrate that high level of
expression of DNMTs is associated with more aggressive
phenotypes of CaP, lower expression of TbRs, and lower
sensitivity to the inhibitory role of TGF-b.
The molecular mechanisms which govern regulation of
DNMTs have been largely unknown [43], and the relationship(s)
between DNMTs and TGF-b in CaP have yet to be explored.
Although other factors like c-Jun may be involved in the process
[44], ERK appears to be an obligatory switch for TGF-b-
mediated expression of DNMTs in CaP, although the effect of
TGF-b on ERK activation remains controversial [45], [46]. More
recently we reported that there was a differential activation of
ERK between benign and malignant cells in response to TGF-b
[14], [47]. In our prior studies involving benign cells, we reported
that TGF-b exposure, ERK inactivation and DNMTs down
regulation contribute to the expression of Foxp3 in benign
immune cells [14]. In the present study, higher expression levels
of DNMTs were found to be associated with CaP with higher
invasive capabilities when compared with CaP cells with lower
invasive capabilities. Interestingly, we found that increased levels
of DNMTs were associated with increased levels of TGF-b and p-
ERK, and decreased levels of TbRs. In contrast, our hypotheses
were verified by a serial of blockade assays, blockade of TGF-b
signaling using the TbRIIDN or neutralizing antibody 1D11,
decreased the levels of DNMTs between 50%–90% in more
invasive cell lines, and to a lesser degree (30–50%) in the less
invasive cell lines. These findings indicate that tumor-derived
TGF-b is a major mediator involved in the regulation of DNMTs
and TbRs in human CaP cells, and this process correlates with
more invasive phenotypes. Meanwhile, down regulation of
DNMT expression by blockade of TGF-b is associated with an
up-regulation of naı ¨ve TbRs expression. These findings, taken
together with results from our previous study, suggest that tumor-
three DNMTs in PC-3 cells. Treatment with 1D11, or MEK inhibitor, UO126 is associated with the down-regulation of all DNMT mRNA expression. D.
(Here we showed most aggressive PC-3M as a sample). There was a significant increase in cell motility through a Matrigel-coated polycarbonate
membrane under the treatment of TGF-b1 (10 ng/mL). The invasion of all CaP cells could be inhibited by blocking the TGF-b signal by 1D11 or using
a p-ERK inhibitor UO126, or DNMT inhibitor 5-Aza separately. The inhibition of invasion by UO126 can’t be reverted by TGF-b treatment. Upper right
panel: Corresponding numbers of invasive cells. Bottom right panel: absorbance values. This result indicates p-ERK mediated TGF-b-induced DNMT
potentiates the invasive ability of prostate cancer cell lines. (magnification, 10610).
doi:10.1371/journal.pone.0025168.g003
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e25168derived TGF-b activates ERK, which mediates the expression of
DNMTs (because blockade of ERK resulted in 50% decrease on
DNMTs expression). DNMTs then methylate the TGF-b receptor
promoter regions resulting in the loss of growth inhibition
mechanisms which we reported earlier [4]. Our present study
also provides insight into the interaction between ERK and
DNMTs in CaP. Exposure to the ERK inhibitor, UO126 results
in .50% reduction in the expression of DNMTs, indicating that
ERK is one of the major regulators of TGF-b induced DNMTs
expression in CaP cells. Our observations of the co-localization of
p-ERK and DNMTs also suggest that only cells which exhibit
ERK activation can express DNMTs, which is evidence that they
are in the same TGF-b activated signal pathway.
Importantly, we found direct evidence that blockade of DNMT
by its inhibitor 5-Aza resulted in decrease in the invasive
capabilities of CaP, as well as the blockade of either TGF-b by
1D11, or blockade of p-ERK by UO126. This data indicates that
DNMT is a major promoter for CaP invasive capabilities. This
procedure is regulated by TGF-b and mediated by p-ERK.
Based upon the above findings, we postulate that tumor-derived
TGF-b can regulate its receptors by a potential feedback loop
which is mediated by activation of ERK. Some other signaling
factors like Serine/threonine protein phosphatases 2 (PP2A) [48]
may be involved in this procedure. P-ERK may subsequently
activate the transcription factors in the DNMTs promoter and
increases the expression of DNMTs which methylates TGF-b
receptor promoter regions resulting in the loss of growth inhibition
mechanisms that are normally induced by TGF-b. Simultaneous-
ly, the downregulation of TbR expression and low level of TGF-b
signaling may act as a positive feedback mechanism to induce the
reflexive stimulation of TGF-b secretion in CaP. These potential
feedback loops could explain the reduced expression of TbRs and
large amounts of TGF-b that have been observed in advanced
CaP. Our in vivo xenograft model also demonstrated that
inhibition of DNMTs correlated to a lower tumor weight and
cancer proliferation rate. These results suggest that the expression
of DNMTs is associated with aggressive malignant phenotypes,
tumor growth, and progression in vivo. In combination with our
Figure 4. TGF-b induced DNMTs is associated with growth of prostate cancer in vivo. A. IVIS 100 imaging system was used to monitor
tumor growth in real-time. We found that tumor growth is inhibited dramatically with the treatment of 1D11 compared with Group 2 (13C4
treatment) and 3 (No treatment control). B. 1D11 treatment inhibits the tumor growth in a time dependent manner. C, At the end of the 45-day
treatment period, mice were sacrificed and tumors were isolated. The average tumor weight and volume was 5.3 g and 6.85 cm
3, respectively in
1D11 treatment group. In comparison, the average weight and volume of tumors in the 10 animals treated with the control 13C4 was significantly
greater at 15.8 g and 12.85 cm
3, respectively. The corresponding values in the mice that received no treatment were 31.4 g and 23.39 cm
3,
respectively (P,0.01 among three groups). D. Immunohistochemical analyses of the primary tumors revealed that the expression of p-ERK, DNMTs in
animals with 1D11 treatment is significantly lower than those of the other two groups.
doi:10.1371/journal.pone.0025168.g004
Figure 5. Confirmation of p-ERK mediated, TGF-b-induced DNMT in TMA specimens obtained at the time of prostatectomy. A.
Immunohistochemical analysis of serial TMA sections from a patient with Gleason’s score of 8, revealed higher expression of TGF-b, p-ERK, DNMTs,
but lower expression of TbRI and TbRII and p-Smad2 as compared to serial sections taken from a patient with a lower Gleason’s grade of 6. These
results are representative of the predominant staining pattern seen in all patient samples/tissue arrays (magnification: 10620). The corresponding
frequency (or percentage) of staining and intensity of staining could be found on B. B. High levels of TGF-b1 expression (Score=3) were identified in
42.3%, 8.9% and 7.0%, p-Erk expression in 36.4%, 6.7% and 13.5%, DNMT1 expression in 27.9%, 1.8% and 1.3%, DNMT3A expression in 40.6%, 11.9%
and 6.7%, and DNMT3B expression in 58.7%, 18.3% and 22.8% of high ($8), intermediate (=7), and low Gleason grade (#6), respectively.
doi:10.1371/journal.pone.0025168.g005
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25168previous findings [4], we found that DNMTs is an important
factor and predictor related to CaP progression.
Furthermore, the close correlation between TGF-b,E R Ka n d
DNMTs intissuemicroarray specimensindicates thatthiscascade of
signal events is likely not only associated with aggressive malignant
phenotypes in vitro, but may also be involved with progression of
CaP in humans. Based on our results, during progression of prostate
cancer, an attenuation of expression of TGF-b receptors facilitates
tumor cells escaping from the growth inhibition by TGF-b which is
Smad dependent.Meanwhile,theSmad-independent pathway,such
as p-ERK and DNMT signaling could be induced by TGF-b and
results in the more aggressive phenotypes.
Our data shows that increased expression of DNMTs is highly
correlated with both the expression levels of TGF-b1 and p-ERK.
Furthermore, there was a significant correlation between the levels
of DNMTs and Gleason grade, which further supports our findings
that DNMTs are associated with more invasive CaP phenotypes.
This finding is similar to recent reports suggesting that DNMT1 is
associated with lung cancer progression [49]. The present results
demonstrate that DNMT1 is associated with biochemical recur-
rence in CaP patients seven years following radical prostatectomy.
Thus, patients with higher tissue expression levels of DNMT1 are at
increased risk for biochemical recurrence compared to those with
lower tissue expression levels. The relationship between DNMT1
Figure 6. TGF-b-induced DNMT1 predicts prostate cancer recurrence. A. Kaplan Meier curve was generated for significant variables. TGF-b1,
p-Smad2, p-ERK, pathologic Gleason Score and DNMT1, TbRI were all predictors of biochemical recurrence. B. DNMT1, pathologic Gleason score was
analyzed as two different groups, and there was a significant difference in the survival curves. C. Cox Proportional Hazards Model only includes
DNMT1, grouped as below 3 and 3, and pathologic Gleason score sum of patients, grouped as below 8, or above. Using our dataset, patients with
tissue level DNMT1 of 3 had a 3.53 times higher biochemical recurrence rate than patients with lower tissue levels of DNMT1. Patients with Gleason
score sum $8 have a 2.27 times higher biochemical recurrence rate compared to patients with Gleason score sum ,8.
doi:10.1371/journal.pone.0025168.g006
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PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e25168expression and biochemical recurrence is independent of Gleason
grade. Although other variables including TGF-b1, p-ERK,
Gleason grade were also showed significantly associated with
biochemical recurrence, the final Cox Proportional Hazards Model
demonstrated that DNMT1, in combination with pathologic
Gleason sum, are stronger predictors for disease outcome. The
exact mechanism of this observation remains unclear, but variables
involved in the signal pathway including tumor expression of
DNMT1, TGF-b1, and p-ERK may be useful in predicting clinical
outcome following radical prostatectomy. High expression level of
DNMT1 was risk factors for biochemical recurrence in men with
CaP, regardless of Gleason’s score.
In summary, our findings indicate that DNMTs expression
levels are correlated with invasive capabilities in cultured human
CaP cell lines. Additionally, we found that tumor-derived TGF-b
and ERK are involved in the regulation of DNMTs in these cell
lines. Inhibition of TGF-b in vivo results in the corresponding
inhibition of DNMTs, and appears to significantly decrease tumor
growth. In addition, we confirmed that the expression levels of
TGF-b, ERK and DNMTs in tissue specimens obtained at the
time of prostatectomy mimicked our findings in cell culture.
Finally, we found that high expression levels of DNMT1 may
potentially be used to predict biochemical recurrence in patients
following radical prostatectomy.
Supporting Information
Figure S1 Immunoblot analyses demonstrated that
after treatment with 5-Aza-29-deoxycytidine (5-Aza), the
expression of TbRI and TbRII in PC-3 increased
dramatically. In contrast, the expression of both TbRI and
TbRII decreased significantly with the treatment of TGF-b and this
change could be recovered when 5-Aza is added (Figure S1A).
Similarly, real-time PCR confirmed that the expression of both
TbRI and TbRII wasincreased 2–2.5 folds after treatment of 5-Aza
in PC-3 cells. Treatment of TGF-b suppressed the expressions of
TbRI and TbRII 46% and 29% respectively (Figure S1B). We also
identified the methylation status of TbRI and TbRII promoters, by
using the same MSP approach and sequencing methodologies (4).
Using this technique, we found the same methylated sites as our
previous study (4) in that cytosine positions 2251, 2231, 2244,
2348, 2356 and 2365 in the promoter of TbRI,and +27,+32 and
2140 for the promoter of TbRII were methylated (Figure S1C).
PC-3 cells also have a portion of TbRI and TbRII promoters that
are unmethylated. Interestingly, treatment with TGF-b increased
the methylation status, but treatment with 5-Aza converted all
methylated sites to unmethylated. The thymidine incorporation
assay indicated that the proliferation of PC-3 cells were only
modestly inhibited modestly by exogenous TGF-b. In comparison,
5-Aza treatment resulted in a significant inhibition of cell
proliferation, regardless of whether exogenous TGF-b was added
into the culture or not. There was no significant difference observed
betweentreatment with both 5-Aza and TGF-b or with 5-Aza alone
(P.0.05) (Figure S1D). Taken together, these results support our
above finding that knockdown of DNA methyltransferases result in
the demethylation of the TGF-b receptors gene promoters and
restoration of TGF-beta inhibition of cell growth. TGF-b
contributes to the methylation of its own receptors. A. Immunoblot
analyses demonstrated that after treatment with 5-Aza-29-deoxycy-
tidine(5-Aza),theexpression of TGF-b receptorI (TbRI) andTGF-
b receptor II (TbRII) in PC-3 increased dramatically. In contrast,
theexpression ofboth TbRI andTbRIIdecreasedsignificantly with
thetreatmentofTGF-bandthischangecouldberecoveredwhen5-
Aza is added. B. Real-time PCR confirmed that the expression of
both TbRI and TbRII was increased 2–2.5 folds after treatment of
5-Aza in PC-3 cells. Treatment of TGF-b suppressed the
expressions of TbRI and TbRII 46% and 29% respectively. C.
The methylation status of TbRI and TbRII promoters was
identified by using the same MSP approach and sequencing
methodologies (4). The methylated sites in cytosine positions 2251,
2231,2244, 2348,2356 and2365inthe promoterof TbRI, and
+27, +32 and 2140 for the promoter of TbRII. PC-3 also has
portion of TbRI and TbRII promoters which are unmethylated.
Interestingly, treatment with TGF-b also increased the methylation
status, but treatment with 5-Aza can convert all methylated sites to
unmethylated. D.Thethymidineincorporationassayindicated that
the proliferation of PC-3 could be inhibited little by exogenous
TGF-b. However, 5-Aza treatment resulted in a significant
inhibition of cell proliferation, regardless of whether exogenous
TGF-b was added into the culture or not. There was no significant
difference observed between treatment with both 5-Aza and TGF-b
or with 5-Aza alone (P.0.05).
(TIF)
Figure S2 For positive control staining for TMA stain-
ing, a tissue (Colon cancer for TGF-b, Breast cancer for
p-ERK, Placenta for DNMT1 and DNMT3A, Breast
cancer for DNMT3B respectively) which is well known
to have expression of target protein was used. Negative
controls were identical array sections stained in the absence of
primary antibody.
(TIF)
Method S1 Supplemental Materials and Methods.
(DOC)
Method S2 NU Pathology Core Facility Standard Oper-
ating Procedure.
(DOC)
Table S1 Secretion of TGF-b in various derivatives of
PC3 cells and benign cells (pg/ml/48 hours/10
5 cells).
(DOC)
Table S2 Clinical and pathologic characteristics of
patients who experienced a radical prostatectomy.
(DOC)
Table S3 Correlation of TGF-b signaling components
and clinical characterics.
(DOC)
Table S4 The variables significantly correlated with
biochemical recurrence.
(DOC)
Table S5 The significant variables selected by Cox
Proportional Hazards Mode.
(DOC)
Letter S1 Northwestern University ACUC Approval
protocol number 2007-0565.
(PDF)
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sity Institutional Review Board (The IRB number is
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